



**EVITRADE
Health
Systems
Corporation**

EVITRADE Health Systems Corporation

EVITRADE LOI with CANTECH Molecular to Include Genetics Technology

VANCOUVER, BC, Friday December 8, 2017 – EVITRADE Health Systems Corp. (CSE:EVA, OTCQB: AXHLF) (the “Company” or “EVITRADE”) announces that the current negotiations on the non-binding LOI is to also include Cantech’s genetics technology. This technology is applicable to a wide range of markets within the medical, recreational cannabis and industrial hemp plant industries, including the emerging market of genetic mapping in both people and domestic animals.

Cantech believes that with their years of field and laboratory work in the plant breeding industry, they are able to apply this experience in a cross disciplinary manner for creating large genetic mapping databases using the latest in next generation genetic sequencing platforms.

The mapping will be done at a molecular level and will have the opportunity to identify the organisms’ general health, as well as any possible diseases that may arise from a genetic perspective (whether plant, animal or human).

The significance of this genetics technology is that it can be coupled along with advanced drug development software; the data obtained from the genetic mapping can assist in determining the best CBD/THC combinations that an individual would be most receptive and responsive to, based on their personal genetics. This will provide the ability to engineer tailor made, patentable drug combinations for the medical cannabis and domestic animal industries and possibly for other pharmacological applications.

Management looks forward to providing further details as to the consideration, final structure and other technologies being negotiated into the definitive agreement as developments on the current CANTECH non-binding Letter of Intent continue to be discussed.

Contact:

Ron Ozols, Director, EVITRADE Health Systems Corporation
(formerly Auxellence Health Corporation)

Email: ceo@auxellence.com or info@auxellence.com

Website: <http://www.auxellence.com>

CSE Micro-site: <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>

About EVITRADE Health Systems Corporation (CSE: EVA, OTCQB: AXHLF)

EVITRADE (formerly Auxellence Health Corp.), was founded in 2013 to provide online health technologies and services for resolving common health problems.



**EViTRADE
Health
Systems
Corporation**

EVITRADE Health Systems Corporation

Disclaimers – Forward Looking Statements

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators which is posted on www.sedar.com, and <http://thecse.com/en/listings/technology/evitrade-health-systems-corp>.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.